N/A N=43 Clinical Utility of Handheld Hydrogen Breathalyzer in Identification of Food Sensitivities (AIRE Study)
SIBO · Small Bowel Bacterial Overgrowth Syndrome
Primary: Hydrogen Content in Parts Per Million (Ppm) — 3.5 ppm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=4 Treating Bacterial Overgrowth in Parkinson's Disease
Parkinson's Disease · Small Intestinal Bacterial Overgrowth
Primary: Change in "Off" Time as Measured by Patient Diary — -1.4; -2.8; -0.9; -2.0 hours
N/A N=115 Is Chronic Abdominal Pain in Pediatric Patients Due to Small Intestinal Bacterial Overgrowth?
Chronic Abdominal Pain · Small Intestinal Bacterial Overgrowth
Primary: The Number of Participants at Baseline With SIBO — 14; 44; 24 Participants
Phase 4 N=74 A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
Irritable Bowel Syndrome
Primary: Change in Mean Daily Abdominal Pain — 5.2; 5.3; 3.9; 3.8 score on a scale — p=0.78
N/A N=103 Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy
HIV-associated Enteropathy
Primary: Frequency of Daily Unformed Bowel Movements — -2.46; -2.16; -2.20 abnormal or unformed stools
N/A N=37 Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
Constipation-predominant Irritable Bowel Syndrome
Primary: Severity of Constipation in Each Arm at Week 1 After Completion of Therapy — 61.2; 28.6 units on a scale
N/A N=53 Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)
Congenital Sucrase-isomaltase Deficiency (CSID)
Primary: Prevalence of CSID Genetic Variants — 27; 0 Participants
N/A N=54 Gulf War Digestive Health Study
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
Phase 4 N=25 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Constipation
Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75
N/A N=50 The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
Irritable Bowel Syndrome With Diarrhea
Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day
N/A N=48 Effects of Low FODMAP Diet on Colonic Epithelial Physiology in Diarrhea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Lactulose Mannitol Excretion — 512.5; 394.5; 456.8; 411 micrograms per ml
Phase 2 N=79 A Study of the Effect of SYN-010 on Subjects With IBS-C
Irritable Bowel Syndrome With Constipation (IBS-C)
Primary: Change From Baseline in the Area Under the Curve (AUC) of Breath CH4 Production at Day 7 — 99.2; 57.3; 72.7 hours*ppm
N/A N=50 Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease
Celiac Disease
Primary: Baseline Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.7; 2.8 Score on a scale
Phase 2 N=565 Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Irritable Bowel Syndrome With Diarrhea
Primary: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With…
N/A N=17 Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)
Diarrhea Predominant Irritable Bowel Syndrome
Primary: Number of Subjects Reporting "Adequate Relief" From IBS Symptoms for the Previous Week. Adequate Relief Was a "True/False" Item. — 13 Participants
Phase 4 N=214 CO2 Versus Air Insufflation for Single-balloon Enteroscopy
Intubation Depth
Primary: Intubation Depth — 323.8; 238.3 cm
Phase 3 N=49 Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth
Parkinson's Disease
Primary: Number of Subjects With Small Bowel Bacterial Overgrowth (SBBO) — 2; 12; 2; 9 participants — p=1.0
Phase 2 N=45 Efficacy and Safety of Rifaximin With NAC in IBS-D
Irritable Bowel Syndrome With Diarrhea
Primary: Change in Stool Form — -0.26; -0.45; -0.49 score on a scale
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
Phase 3 N=2,583 Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
Irritable Bowel Syndrome With Diarrhea
Primary: Repeat Treatment Responders — 32.6; 25.0 percentage of patients — p=0.0232
Phase 3 N=637 Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
Non-Constipation Irritable Bowel Syndrome
Primary: Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6). — 32.2…
Phase 3 N=623 Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
Non-Constipation Irritable Bowel Syndrome
Primary: Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6). — 31.2…
N/A N=40 The Value of Bio-electrical Impedance Analysis in Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Comparison of the Phase Angle Between IBS Patients and Healthy Individuals — 5.78; 6.35 degrees
N/A N=225 Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders
Irritable Bowel Syndrome · Colitis, Ulcerative · Crohn Disease
Primary: Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms — 40; 30; 23; 23 microbial species population
N/A N=92 Dietary Supplement With and Without a Probiotic and/or Antibiotic
Healthy Adults
Primary: Evaluation of the Changes in Microbiome Species Abundance and Diversity From Baseline Until End of Study (Day 35) — 27.00; 31.25; 27.00; 27.00 copies/ng DNA — p=<0.0001
Phase 2 N=9 Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
Short Bowel Syndrome
Primary: Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE) — 9; 5; 3; 1 Participants
Phase 3 N=61 The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study
Irritable Bowel Syndrome
Primary: Change in Average Overall Bowel Symptom Score (BSS) After an 8 Week Treatment Period — -4; -13 score on a scale
N/A N=42 Study Evaluating the Digestibility of Serum-Derived Bovine Immunoglobulin Protein Isolate in Healthy Adults
Healthy
Primary: Concentration of Total Plasma Amino Acids — 2730.87; 2988.94; 2964.19; 2869.14 umol/mL
Phase 2 N=12 Blood Lipopolysaccharide (LPS) Rifaximin Study
Obese · Insulin Resistance · Metabolic Syndrome
Primary: Circulating LPS — 2.44; 1.86; 13.66; 10.00 EU/mL — p=>0.05
Phase 2 N=48 SH-DS01 on Fecal Metagenomic Stability
Irritable Bowel Syndrome
Primary: Safety and Tolerability of DS-01 Treatment vs Placebo — 0; 0 Participants